A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma.

MLA

De Jesus-Acosta, Ana, et al. “A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma.” Investigational New Drugs, vol. 32, no. 4, Aug. 2014, pp. 739–45. EBSCOhost, https://doi.org/10.1007/s10637-014-0083-8.

APA

De Jesus-Acosta, A., Laheru, D., Maitra, A., Arcaroli, J., Rudek, M. A., Dasari, A., Blatchford, P. J., Quackenbush, K., & Messersmith, W. (2014). A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Investigational New Drugs, 32(4), 739–745. https://doi.org/10.1007/s10637-014-0083-8

Chicago

De Jesus-Acosta, Ana, Daniel Laheru, Anirban Maitra, John Arcaroli, Michelle A Rudek, Arvind Dasari, Patrick J Blatchford, Kevin Quackenbush, and Wells Messersmith. 2014. “A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma.” Investigational New Drugs 32 (4): 739–45. doi:10.1007/s10637-014-0083-8.